Post Approval Study of the remedē System

NCT ID: NCT03425188

Last Updated: 2021-04-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

53 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-28

Study Completion Date

2020-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, single arm cohort study to evaluate the long-term safety, long-term effectiveness, and survival rate in subjects implanted with the remedē System.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Post Approval Study is a multi-center, prospective, single arm cohort study to evaluate the long-term safety, long-term effectiveness, and survival rate in subjects implanted with the remedē System from the remedē System Pivotal Trial. Only subjects who were implanted and actively being followed as part of the remedē System Pivotal Trial are eligible. An individual subject's participation is expected to continue to five years post remedē System implant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

remedē System Subjects

Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who were previously implanted with the remedē System and participated in the remedē System Pivotal Trial
* In the investigator's opinion, willing and able to comply with all study requirements
* Signed Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent (including Health Insurance Portability and Accountability Act \[HIPAA\] authorization in the US)

Exclusion Criteria

* There are no criteria by which a subject would be excluded
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Respicardia, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robin Germany, MD

Role: STUDY_DIRECTOR

Respicardia, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Keck Medical Center of USC

Los Angeles, California, United States

Site Status

UF Health Jacksonville

Jacksonville, Florida, United States

Site Status

Advocate Good Samaritan Hospital

Downers Grove, Illinois, United States

Site Status

University of Maryland, Baltimore

Baltimore, Maryland, United States

Site Status

United Heart and Vascular Clinic

Saint Paul, Minnesota, United States

Site Status

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Site Status

Washington University in St. Louis

St Louis, Missouri, United States

Site Status

Nebraska Heart Institute

Lincoln, Nebraska, United States

Site Status

Cooper Health System

Cherry Hill, New Jersey, United States

Site Status

Novant Clinical Research Institute Forsyth Medical Center

Winston-Salem, North Carolina, United States

Site Status

The Lindner Center for Research & Education at The Christ Hospital

Cincinnati, Ohio, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Wesley Neurology

Cordova, Tennessee, United States

Site Status

Methodist Hospital

San Antonio, Texas, United States

Site Status

Marshfield Clinic

Marshfield, Wisconsin, United States

Site Status

Herz-und Diabeteszentrum NRW

Bad Oeynhausen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Germany

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR1079

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Precision Sleep Medicine
NCT06903481 COMPLETED
Janus II Feasibility
NCT06556693 RECRUITING NA